Docoh
Loading...

CALA Calithera Biosciences

GRANT
Utility
Ectonucleotidase inhibitors and methods of use thereof
28 Dec 21
The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof.
Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
Filed: 27 Sep 19
GRANT
Utility
Ectonucleotidase inhibitors and methods of use thereof
16 Nov 21
The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof.
Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
Filed: 27 Sep 19
GRANT
Utility
Ectonucleotidase inhibitors and methods of use thereof
3 Aug 21
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Lijing Chen, Roland Joseph Billedeau, Jim Li
Filed: 20 Jun 19
GRANT
Utility
Ectonucleotidase inhibitors and methods of use thereof
15 Jun 21
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Roland J. Billedeau, Jim Li, Lijing Chen
Filed: 19 Dec 19
GRANT
Utility
Compositions and methods for inhibiting arginase activity
1 Jun 21
The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure.
Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
Filed: 14 Feb 20
GRANT
Utility
Combination therapy with glutaminase inhibitors and immuno-oncology agents
9 Mar 21
The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
Filed: 1 Feb 19
GRANT
Utility
Compositions and methods for inhibiting arginase activity
2 Feb 21
The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent.
Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
Filed: 29 Jul 19
GRANT
Utility
Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
2 Feb 21
A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
Michael C. Van Zandt, Jennifer L. Savoy
Filed: 18 Nov 19
GRANT
Utility
Compositions and methods for inhibiting arginase activity
30 Nov 20
The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention.
Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
Filed: 9 Aug 18
GRANT
Utility
Compositions and methods for inhibiting arginase activity
23 Nov 20
The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention.
Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
Filed: 22 Mar 20
GRANT
Utility
Heterocyclic glutaminase inhibitors
5 Oct 20
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy Friend Stanton, Eric Brian Sjogren
Filed: 14 Nov 13
GRANT
Utility
Crystal forms of glutaminase inhibitors
8 Jun 20
The invention relates to crystalline salts of a compound having the structure of formula (I), methods for their preparation, and related pharmaceutical compositions comprising the crystalline salt.
Timothy F. Stanton, James J. Springer, Jacqueline N. Williams
Filed: 6 Jun 19
GRANT
Utility
Compositions and methods for inhibiting arginase activity
23 Mar 20
The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure.
Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
Filed: 28 Mar 19
GRANT
Utility
Ectonucleotidase inhibitors and methods of use thereof
24 Feb 20
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Roland J. Billedeau, Jim Li, Lijing Chen
Filed: 20 Dec 17
GRANT
Utility
Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide
2 Dec 19
A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
Michael C. Van Zandt, Jennifer L. Savoy
Filed: 10 May 18
GRANT
Utility
Ectonucleotidase inhibitors and methods of use thereof
11 Nov 19
The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof.
Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
Filed: 7 Sep 17
GRANT
Utility
Treatment of lung cancer with inhibitors of glutaminase
14 Oct 19
The invention relates to methods of treating lung cancer using glutaminase inhibitors.
Francesco Parlati, Melissa G. Works, Mirna L. M. Rodriguez, Dong Zhang
Filed: 5 Apr 16
  • 1
Patents are sorted by USPTO publication date, most recent first